Guess Who Picked Up Enstar Group Ltd (NASDAQ:ESGR) Shares

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Enstar Group Ltd (NASDAQ:ESGR)reported that Beck Mack & Oliver Llc. has picked up 806,092 of common stock as of 2017-04-28.

The acquisition brings the aggregate amount owned by Beck Mack & Oliver Llc. to a total of 806,092 representing less than 4.91% stake in the company.

For those not familiar with the company, Enstar Group Limited is an insurance group that offers capital release solutions and specialty underwriting capabilities through its network of group companies in Bermuda, the United States, the United Kingdom, Continental Europe, Australia and other international locations. The Company’s segments include Non-Life Run-Off, Atrium, StarStone, and Life and Annuities. The Non-life Run-off segment comprises the operations of its subsidiaries that are running off their property and casualty and other non-life lines of business. The Atrium segment underwrites specialist marine, energy, aerospace, non-marine and liability classes. The StarStone segment offers a range of property, casualty and specialty insurance products. The Life and Annuities Segment consists of the operations managing the Company’s closed-block of life and annuity business, and its life settlements business.

A glance at Enstar Group Ltd (NASDAQ:ESGR)’s key stats reveals a current market capitalization of 3.74 Billion based on 16.18 Million shares outstanding and a price at last close of $194.10 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2013-08-15 Lestrange picked up 500 at a purchase price of $136.44. This brings their total holding to 2,000 as of the date of the filing.

On the sell side, the most recent transaction saw Rajpal unload 343,487 shares at a sale price of $158.50. This brings their total holding to 322,061.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Enstar Group Ltd (NASDAQ:ESGR) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Here’s Who Picked Aehr Test Systems (NASDAQ:AEHR) Shares

aehr

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Aehr Test Systems (NASDAQ:AEHR) reported that Schneider John M. has picked up 145,218 of common stock as of 2017-04-28.

The acquisition brings the aggregate amount owned by Schneider John M. to a total of 145,218 representing less than 0.68% stake in the company.

For those not familiar with the company, Aehr Test Systems is engaged in the designing, manufacturing and marketing of advanced test and burn-in products to the semiconductor manufacturing industry. The Company manufactures and markets full wafer contact test systems, test during burn-in systems, test fixtures, die carriers and related accessories. The Company’s principal products are the Advanced Burn-In and Test System (ABTS), the FOX full wafer contact parallel test and burn-in systems, WaferPak full wafer contactor, the DiePak carrier and test fixtures. The Company develops, manufactures and sells systems, which are designed to reduce the cost of testing and to perform reliability screening, or burn-in, of complex logic devices, memory integrated circuits (ICs), sensors and optical devices. These systems can be used to perform parallel testing and burn-in of packaged ICs, singulated bare die or ICs still in wafer form.

A glance at Aehr Test Systems (NASDAQ:AEHR)’s key stats reveals a current market capitalization of 83.34 Million based on 16.79 Million shares outstanding and a price at last close of $4.76 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2015-08-17 Anderson picked up 1,500 at a purchase price of $2.22. This brings their total holding to 429,009 as of the date of the filing.

On the sell side, the most recent transaction saw Hendrickson unload 5,000 shares at a sale price of $4.83. This brings their total holding to 15,663.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Aehr Test Systems (NASDAQ:AEHR) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Why CytRx Corporation (NASDAQ:CYTR) Stock Could Keep Dropping

CytRx Corporation (NASDAQ:CYTR) shares were down 15.02% on Thursday to $0.685 and an additional 7.65% in after-hours trading to $0.632. The company has a market cap of $75.70 million at 117.32 million shares outstanding. Share prices have been trading in a 52-week range of $0.36 to $3.46.

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. It is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy.

The company is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi’s sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.

Earlier this month, CytRx Corporation announced that an abstract describing results from its global Phase 3 clinical trial evaluating aldoxorubicin versus investigators’ choice in patients with relapsed and refractory soft tissue sarcomashas been selected for an oral presentation at the 2017 American Society of Clinical Oncology in June.

We look forward to presenting the more detailed and updated global Phase 3 results to the medical community at ASCO this year,” said Daniel Levitt, M.D., Ph.D., Chief Operating Officer and Chief Medical Officer of CytRx Corporation.  “The Phase 3 trial and the combination trial of aldoxorubicin with ifosfamide continue to build on our prior studies showing the utility of aldoxorubicin as a treatment for patients with STS.  These trials, together with our other clinical and pre-clinical studies of aldoxorubicin, will support our planned New Drug Application submission.”

However, the gains were quickly faded when CytRx Corporation recently announced a proposed public offering of its common stock that is subject to market conditions. The company plans to use the proceeds for working capital and general corporate purposes, including clinical and regulatory activities, new drug discovery activities, and possible future strategic transactions.

Also, there an be no assurance as to whether or when the offering may be consummated, or as to the actual size or terms of the offering. H.C. Wainwright & Co. is acting as exclusive placement agent for the offering.

DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.

Edenbrook Capital is Buying Yume Inc (NYSE:YUME) Shares

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Yume Inc (NYSE:YUME) reported that Edenbrook Capital, Llc has picked up 2,148,206 of common stock as of 2017-04-27.

The acquisition brings the aggregate amount owned by Edenbrook Capital, Llc to a total of 2,148,206 representing less than 6.31% stake in the company.

For those not familiar with the company, YuMe, Inc. (YuMe) is an independent provider of multi-screen video advertising technology, connecting brand advertisers, digital media property owners and consumers of video content across a range of Internet-connected devices. The Company operating segments include Domestic and International. The Company offers advertising customers end-to-end marketing solutions by combining data-driven technologies with deep insight into audience behavior. The Company also offers demand-side platform (DSP), called YuMe for Advertisers, to find relevant audiences and deliver targeted advertising, and a supply-side platform (SSP), called YuMe for Publishers (YFP 5.0), which helps aggregate audiences, define audience characteristics and offer monetization opportunities for digital media property owners. Its technologies serve the specific needs of brand advertisers and enable them to find and target brand-receptive audiences across a range of Internet connected devices and digital media properties.

A glance at Yume Inc (NYSE:YUME)’s key stats reveals a current market capitalization of 143.31 Million based on 34.04 Million shares outstanding and a price at last close of $4.19 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-03-28, Singer picked up 19,557 at a purchase price of $3.69. This brings their total holding to 2,339,594 as of the date of the filing.

On the sell side, the most recent transaction saw Carvalho unload 475 shares at a sale price of $5.11. This brings their total holding to 48,177.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Yume Inc (NYSE:YUME)
as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Furlow Blake Picked Creative Learning Corporation (OTCMKTS:CLCN) Shares

clcn

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Creative Learning Corporation (OTCMKTS:CLCN) reported that Furlow Blake has picked up 417,600 of common stock as of 2017-04-27.

The acquisition brings the aggregate amount owned by Furlow Blake to a total of 417,600 representing less than 3.9% stake in the company.

For those not familiar with the company, Creative Learning Corporation offers educational and enrichment programs to children ages 3 to 13+ through its franchisees. The Company, through its subsidiary BFK Franchise Company, LLC (BFK), offers a franchise concept known as Bricks 4 Kidz, a mobile business operated by franchisees within a specific geographic territory offering project-based programs designed to teach principles and methods of engineering to children between the ages of 3 and 13. The Company, through its subsidiary SF Franchise Company, LLC, offers a third franchise concept known as Sew Fun Studios. Sew Fun Studios is a mobile business operated by franchisees within a specific geographic territory offering creative project-based activities, classes and programs in fashion and interior design and sewing to children and adults. As of September 30, 2016, the Company had 710 Bricks 4 Kidz and Sew Fun Studios franchises, 28 Bricks 4 Kidz master franchises, and 20 Bricks 4 Kidz sub-franchises operating in 38 countries.

A glance at Creative Learning Corporation (OTCMKTS:CLCN)’s key stats reveals a current market capitalization of 2.78 Million based on 11.94 Million shares outstanding and a price at last close of $0.230 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2015-06-18, Pappas picked up 4,600 at a purchase price of $0.60. This brings their total holding to 1,875,667 as of the date of the filing.

On the sell side, the most recent transaction saw Pappas unload 26,029 shares at a sale price of $0.15. This brings their total holding to 1,713,429.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Creative Learning Corporation (OTCMKTS:CLCN) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Guess Who Picked Sanchez Energy Corp (NYSE:SN) Shares

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Sanchez Energy Corp (NYSE:SN) reported that Sanchez Antonio R Jr has picked up 6,194,036 of common stock as of 2017-04-27.

The acquisition brings the aggregate amount owned by Sanchez Antonio R Jr to a total of 6,194,036 representing less than 7.9% stake in the company.

For those not familiar with the company, Sanchez Energy Corporation is an independent exploration and production company. The Company is focused on the acquisition and development of the United States onshore unconventional oil and natural gas resources. The Company primarily focuses on the Eagle Ford Shale in South Texas. The Company also holds an undeveloped acreage position in the Tuscaloosa Marine Shale (TMS) in Mississippi and Louisiana. As of December 31, 2016, it had assembled approximately 278,000 net leasehold acres in the Eagle Ford Shale. As of December 31, 2016, it had 473 net wells in the Eagle Ford Shale area. In its Catarina area, the Company had approximately 106,000 net acres in Dimmit, LaSalle and Webb Counties, Texas, at December 31, 2016. In its Maverick area, it had approximately 100,000 net acres in Dimmit, Frio, LaSalle, Zavala and McMullen Counties, Texas, at December 31, 2016. In its Javelina area, it had approximately 39,500 net acres in LaSalle and Webb Counties, Texas, at December 31, 2016.

A glance at Sanchez Energy Corp (NYSE:SN)’s key stats reveals a current market capitalization of 611.49 Million based on 81.90 Million shares outstanding and a price at last close of $7.71 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2015-11-25, Carney picked up 500 at a purchase price of $4.95. This brings their total holding to 500 as of the date of the filing.

On the sell side, the most recent transaction saw Sanchez unload 35,170 shares at a sale price of $8.31. This brings their total holding to 251,485.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Sanchez Energy Corp (NYSE:SN) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Here is Who Just Picked Ptc Therapeutics Inc. (NASDAQ:PTCT)

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Ptc Therapeutics Inc. (NASDAQ:PTCT) reported that Complete Pharma Holdings Ii, Llc. has picked up 6,683,598 of common stock as of 2017-04-27.

The acquisition brings the aggregate amount owned by Complete Pharma Holdings Ii, Llc. to a total of 6,683,598 representing less than 16.2% stake in the company.

For those not familiar with the company, PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.

A glance at Ptc Therapeutics Inc. (NASDAQ:PTCT)’s key stats reveals a current market capitalization of 420.63 Million based on 34.56 Million shares outstanding and a price at last close of $12.01 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-03-03, Rothera picked up 2,000 at a purchase price of $6.23. This brings their total holding to 5,125 as of the date of the filing.

On the sell side, the most recent transaction saw Almstead unload 78 shares at a sale price of $11.82. This brings their total holding to 2,687.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Ptc Therapeutics Inc. (NASDAQ:PTCT) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Oncomed Pharmaceuticals Inc. (NASDAQ:OMED) is Attracting Smart Money

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Oncomed Pharmaceuticals Inc (NASDAQ:OMED) reported that Biotechnology Value Fund L P has picked up 1,372,923 of common stock as of 2017-04-27.

The acquisition brings the aggregate amount owned byBiotechnology Value Fund L P to a total of 1,372,923 representing less than 3.6% stake in the company.

For those not familiar with the company, OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.

A glance at Oncomed Pharmaceuticals Inc (NASDAQ:OMED)’s key stats reveals a current market capitalization of 160.50 Million based on 37.62 Million shares outstanding and a price at last close of $4.00 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2015-09-30, Lasersohn picked up 9,120 at a purchase price of $16.26. This brings their total holding to 46,560 as of the date of the filing.

On the sell side, the most recent transaction saw Lewicki unload 5,711 shares at a sale price of $9.06. This brings their total holding to 22,937.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Oncomed Pharmaceuticals Inc (NASDAQ:OMED) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Skip to content